CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 37 enrolled
Drug / intervention
peg-IFN-α +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02328755
NCT02328755Phase 2Completed
CompareCT.gov

Targeting Cross-presentation With Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in High Risk Acute Myeloid Leukemia

University of Michigan Rogel Cancer Center·interventional·Posted Dec 31, 2014·Updated Oct 6, 2021

In Brief

A Phase 2 clinical trial evaluating peg-IFN-α, Hematopoietic Cell Transplant (HCT), and 2 other interventions for Acute Myeloid Leukemia. Completed, enrolled 37 participants across 1 site.

Detailed Summary

This protocol is an open label, single arm, non-randomized, phase I / II clinical trial investigating the use of pegylated interferon alpha-2a (peg-IFN-α, Pegasys®, Genentech) for prevention of relapse in acute myeloid leukemia (AML) not in remission at the time of allogeneic hematopoietic stem cell transplantation (HCT).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 31, 2014
Enrollment StartJan 1, 2015
Primary CompletionMar 25, 2019
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 11.5 years ago

Interventions

peg-IFN-αdrug

Hematopoietic Cell Transplant (HCT)procedure

Tacrolimusdrug

Calcineurin inhibitor administered along with HCT for Graft Versus Host Disease (GVHD) prophylaxis. Cyclosporine may be substituted if patients cannot tolerate tacrolimus.

Methotrexatedrug

Administered along with HCT for Graft Versus Host Disease (GVHD) prophylaxis.